Clinical trial · Observational
Lung Cancer Early Molecular Assessment Trial
NCT02894853CI-TRIAL-00029539LEMAunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators hypothesize that an early molecular profiling, that includes both tissue and blood-bases analysis, for all NSCLC patients, including stage I-III, will increase diagnostic efficiency. When molecular profiles are available at an earlier stage of disease, more patients will benefit from personalized therapy once needed. This will result in both a better quality of life and outcome.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Liquid (blood) biopsies and tumor biopsy (optional) | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The percentage of patients with EGFR mutation or ALK translocation using the combined tumour tissue and liquid biopsy analysis
- timeFrame
- 3 years
- description
- Patients with EGFR mutation or ALK translocation using the combined tumour tissue and liquid biopsy analysis
Secondary outcomes (4)
- measure
- Include the test performance of both techniques in different stage of disease
- timeFrame
- 3 years
- description
- Test performance of both techniques in different stage of disease
- measure
- The percentage of patients with a predefined actionable genetic alteration
- timeFrame
- 3 years
- description
- Patients with a predefined actionable genetic alteration
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Suspicion of lung carcinoma or established NSCLC but awaiting start of definitive treatment * Written informed consent to undergo diagnostic procedure and molecular analysis of the disease. Exclusion Criteria: * Not motivated to receive any treatment at any point in time. Patients who consider undergoing treatment in the future are eligible.
References
Publications (1)
- DERIVEDSchuurbiers M, Huang Z, Saelee S, Javey M, de Visser L, van den Broek D, Heuvel MVD, Lovejoy AF, Monkhorst K, Klass D. Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC. J Immunother Cancer. 2022 Feb;10(2):e004064. doi: 10.1136/jitc-2021-004064. PMID 35217576